AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Freed Nvidia engineer Avinatan Or meets Jensen Huang at U.S. headquarters
2
Oracle’s stock has fallen 40% since Safra Catz announced her exit. Its latest earnings didn’t calm investors.
3
After over $390 million in funding, Believer Meats abruptly shuts down
4
Israel’s quantum boom: Startups hit $500 million in funding in 2025
5
BlackRock in talks for major investment in creative-tech firm Artlist
More news

Teva

20 stories about Teva
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Legal Troubles Could Weigh Down Teva’s Ability to Carry its Debt Covenants

16.05.19|Uri Tal-Tenne
On one hand, Teva is facing lawsuits that could end up costing it hundreds of millions of dollars; on the other hand, new profitable drugs and a cost-cutting reorganization program. Is it enough to keep its head above water?
מטה חברת טבע תרופות

This Is how Teva and 19 of its Rivals Fixed U.S. Drug Prices

15.05.19|Hezi Sternlicht, Ran Abramson, and Tomer Ganon
A 524-page civil lawsuit filed Friday in the U.S. alleges that 20 generic drugmakers colluded to influence drug prices, with executives meeting regularly to set prices and split the market
הבורסה לניירות ערך רחוב אחוזת בית תל אביב

Teva no Longer Largest Company on TASE After U.S. Legal Troubles Sink Stock

13.05.19|Lilach Baumer
International Flavors & Fragrances (IFF), which listed on the Tel Aviv exchange in October following its acquisition of Israel-based Frutarom, has now surpassed the Israeli drugmaker
מטה חברת טבע תרופות

Teva’s Shady Legal Past Still Weighs on the Debt-Laden Pharma Company

12.05.19|Hezi Sternlicht
On Friday, 43 states joined Connecticut in filing a lawsuit against senior Teva executives and against over a dozen former and current senior executives at leading generic drug companies, alleging all were involved in a drug price-fixing conspiracy
כנס קנאביס פרי דוידסון סאייקי מדיקל

For Medical Cannabis Users, the Biggest Problem Is a Consistent Dose, Says Syqe Medical CEO

07.05.19|Orna Yefet
Perry Davidson, founder and CEO of cannabis inhaler company Syqe Medical, spoke Monday at Calcalist's cannabis conference in Tel Aviv
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva’s Copaxone Successors Are Still Far From Success

05.05.19|Hezi Sternlicht
Teva’s first quarter report for 2019, published Thursday, shows that while the drugmaker is progressing with its financial rehabilitation program, its net debt to EBITDA ratio is leaving the company in dangerous waters
קרית שמונה קריית שמונה

Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI

02.05.19|Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
אתר טבע כפר סבא

Teva Discontinues Development of Cluster Headache Drug

24.04.19|Tzally Greenberg
Under Teva’s brand name Ajovy, fremanezumab has already been approved in the U.S. and Europe as a preventative migraine treatment
מטה טבע פתח תקווה

FDA Approves Teva’s Generic Nasal Spray for Opioid Overdose

21.04.19|Lilach Baumer
Commonly known as Narcan, the spray is considered a life-saving medication, and Teva’s drug is the first generic product approved that does not require medical training to use
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Execs Topped TASE's High Earners List for 2018

18.04.19|Gil Kalian
With nearly $34 million added to the bank, Teva’s CEO Kåre Schultz was the highest earning executive on the Tel Aviv Stock Exchange last year
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Market Indifferent to European Approval of Teva's Migraine Drug

02.04.19|Lilach Baumer
Teva's injection, one of three similar migraine drugs already approved in the U.S., is the third to receive European approval after Amgen Inc. and Novartis AG and Eli Lilly
חברת ה תרופות טבע Teva

Teva Makes Headway in European Copaxone Patent Case

01.04.19|Lilach Baumer
Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court
מפעל טבע הר חוצבים ירושלים

Bidder Contests Teva Sale of Jerusalem Facility

31.03.19|Amitai Gazit and Lilach Baumer
Earlier this month, Teva agreed to sell the land tenure rights of its two Jerusalem factories, set to close by the end of 2019, for a combined $77 million
מטה טבע פתח תקווה

Teva Settles Patent Litigation Case for Blood Sugar Stabilizer With Novo Nordisk

24.03.19|CTech
Under the settlement agreement, Teva will be able to sell a generic version of the drug as of 2023
מפעל חברת טבע הר חוצבים ירושלים

Teva Selling Jerusalem Land Tenure Rights Ahead of Factory Closures

20.03.19|Golan Hazani
Teva currently has two manufacturing plants in Jerusalem, both slated for closure by the end of 2019
נסיעת בכורה של רכבת מהירה מ ירושלים ל תל אביב

Copaxone-Competitor Developer Mapi Pharma Gets Funding for Jerusalem Plant

19.03.19|Lilach Baumer
The clinical-stage company develops more efficient versions of existing successful drugs, including a long-acting version of Teva's multiple sclerosis cash cow
דוד לוסטיג סמנכ"ל בכיר מנהל התפעול טבע ישראל

Senior Vice President David Lustig Leaving Teva After 25 Years

19.03.19|Tzally Greenberg
Lustig will be replaced by Miran Denac, currently senior vice president and cluster manager for central and Western Europe operations
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Morgan Stanley Downgrades Teva From Overweight to Equal Weight

07.03.19|Hezi Sternlicht
The bank upgraded Teva to overweight in November, setting a target price of $27, at the time a 20% premium on the company’s trading price
קאר שולץ מנכל טבע

Teva’s Schultz is Running Out of Rope

14.02.19|Hezi Sternlicht
In the fourth quarter and annual earnings reported by the company Wednesday, Teva missed analyst consensus for non-GAAP earnings per share, and shareholders seem to be losing patience
מנכ"ל טבע החדש קור שולץ 2

Teva to Close 11 More Manufacturing Facilities in 2019

14.02.19|Lilach Baumer
The drugmaker published its fourth quarter and annual reports Wednesday, dropping almost 8% on NYSE after forecasting a steep cut in profits for 2019
Previous ArticlesMore Articles